Reneo Pharmaceuticals, Inc. (RPHM)
|Net Income (ttm)||-19.47M|
|Trading Day||April 9|
|Day's Range||13.48 - 16.50|
|52-Week Range||0.00 - 16.50|
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, g...
Reneo Pharmaceuticals, a Phase 2 biotech developing therapies for rare genetic mitochondrial diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Reneo Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.
Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo Pharmaceuticals is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. We are initially developing REN001 in three rare genetic diseases that typically present with myopathy and have high unmet medical nee... [Read more...]
|Stock Exchange |
|Ticker Symbol |